Collette Mehring, D.O. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 137 W High St, Suite 1a, Elkton, MD 21921 Phone: 410-620-9200 Fax: 410-620-9207 |
Martin F Gavin, D.O. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 137 W High St, Suite 1a, Elkton, MD 21921 Phone: 410-620-9200 Fax: 410-620-9207 |
Helen Chang-deguzman, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 137 W High St, Suite 1a, Elkton, MD 21921 Phone: 410-620-9200 Fax: 410-620-9207 |
News Archive
Some patients infected with the novel coronavirus may experience only mild symptoms, while others may need medical care due to severe illness. People who are at a high risk of developing severe coronavirus disease (COVID-19) include older adults and those with underlying health conditions. However, severe disease has also been seen in young people with no underlying disease.
Elsevier, the world-leading publisher of scientific, technical and medical information products and services, announced today that it will contribute to Doctors Without Borders/M-decins Sans Fronti-res through 'The Great Giveback' campaign, providing medical assistance and support to numerous people around the world.
Researchers at The University of Texas M. D. Anderson Cancer Center have figured out a key molecular step by which a cancer cell can unhook itself from the mesh weave of other cancer cells in a tumor, and move away to a different part of the body - the process, known as metastasis, that makes cancer so dangerous.
Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today that experiments performed in the laboratory of Massachusetts General Hospital (MGH) faculty member Warren M. Zapol, MD, Emeritus Anesthetist-in-Chief and Director of the MGH Anesthesia Center for Critical Care Research, on BTI's new oxygen carrier for traumatic shock and ischemia, IPOXYNTM, will be presented at the "XIII International Symposium on Blood Substitutes and Oxygen Therapeutics" to be held July 27th-29th at MGH.
mOm has raised £630,000 in seed funding from a prominent set of investors to further develop its revolutionary baby incubator. Led by MaSa Partners (a US-based impact fund), investors include Holly Branson (as part of the Virgin Group), Lord Rumi Verjee (as part of the The Rumi Foundation), Continuity Capital, Dr. Joshua Boger, Johannes Heine, Rockspring, and The London Co Investment Fund.
› Verified 4 days ago